EW$83.4
$83.5
Chart
Performance
Key Stats
AI EW Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyEdwards Lifesciences shows strong fundamental performance, particularly in profitability and balance sheet health, with positive long-term thematic tailwinds. Technical indicators are mixed, suggesting potential short-term volatility but an overall bullish long-term outlook.
Thematic
Edwards Lifesciences is well-positioned to benefit from increasing demand for advanced cardiovascular disease treatments and minimally invasive procedures.
Fundamental
Edwards Lifesciences demonstrates strong profitability, robust revenue growth, and a healthy balance sheet, indicating solid financial health and operational efficiency.
Technical
The stock price is below key moving averages on multiple timeframes, and most oscillators suggest selling pressure or a neutral outlook, indicating a short-to-medium term downtrend or consolidation.
| Factor | Score |
|---|---|
| Aging Global Population | 90 |
| Minimally Invasive Procedures | 95 |
| Healthcare Innovation & R&D | 85 |
| Regulatory Landscape (Medical Devices) | 75 |
| Economic Sensitivity | 70 |
| Factor | Score |
|---|---|
| Valuation | 65 |
| Profitability | 95 |
| Growth | 80 |
| Balance Sheet Health | 95 |
| Cash Flow Generation | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 50 |
| Support & Resistance | 60 |
| Volume & Oscillators | 55 |
| Short-Term Trend | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (9)
Consistent EPS Beat
The company has consistently surpassed earnings per share (EPS) estimates for the last 12 months, with an average surprise of 3.45%.
Undervalued Relative to Peers
The Price-to-Earnings (P/E) ratio of 31.32 is lower than the industry average of 35.0, suggesting potential undervaluation.
Bearish Points (10)
High P/E Ratio
The trailing P/E ratio of 31.32 is elevated, suggesting that investors are paying a premium for each dollar of earnings, which could imply future price volatility if growth expectations are not met.
Slowing Revenue Growth
Quarterly revenue growth for Q1 2025 was 25.3%, a deceleration from the 2024 Q4 net margin of 27.8%, potentially indicating a slowdown in sales expansion.
Calendar
July 2025
25
Next Earnings Date
H: $0.65
A: $0.60
L: $0.56
H: 1.50B
A: 1.47B
L: 1.44B
Profile
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Seasonals
Price Target
81.99 USD
The 39 analysts offering 1 year price forecasts for EW have a max estimate of 95.00 and a min estimate of 61.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in transcatheter aortic valve replacement (TAVR) systems (Evolut valve), surgical heart valves, and cardiac rhythm management.
Weight: 95
Major competitor in structural heart therapies (e.g., MitraClip, Portico TAVR), surgical heart valves, and broad cardiovascular medical devices.
Weight: 92
Competitor in structural heart devices (e.g., ACURATE neo2 TAVR in Europe, WATCHMAN), peripheral interventions, and general cardiology.
Weight: 90
Leading provider of patient monitoring solutions, critical care systems, and image-guided therapy, directly competing in Edwards' critical care segment.